Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Andress

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Journal of the American Society of Nephrology : JASN|December 24, 2004
Serum phosphate levels and mortality risk among people with chronic kidney diseaseBryan Kestenbaum, Joshua N Sampson, Kyle D Rudser, et al.
Kidney International|October 22, 2004
Survival following parathyroidectomy among United States dialysis patientsBryan Kestenbaum, Dennis L Andress, Stephen M Schwartz, et al.
Cancer Research|September 15, 2000
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.
Kidney International. Supplement|February 1, 1986
Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTHH G Nebeker, D L Andress, D S Milliner, et al.
Annals of Internal Medicine|December 1, 1984
Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophyD S Milliner, H G Nebeker, S M Ott, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2006
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKDDaniel Coyne, Muralidhar Acharya, Ping Qiu, et al.
Kidney International|June 1, 1987
Bone histologic response to deferoxamine in aluminum-related bone diseaseD L Andress, H G Nebeker, S M Ott, et al.
Growth Regulation|March 1, 1995
IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domainB A Booth, M Boes, D L Andress, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 1, 1985
Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndromeK C Norris, P W Crooks, H G Nebeker, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Journal of the American Society of Nephrology : JASN|December 24, 2004
Serum phosphate levels and mortality risk among people with chronic kidney diseaseBryan Kestenbaum, Joshua N Sampson, Kyle D Rudser, et al.
Kidney International|October 22, 2004
Survival following parathyroidectomy among United States dialysis patientsBryan Kestenbaum, Dennis L Andress, Stephen M Schwartz, et al.
Cancer Research|September 15, 2000
Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injuryS R Ritland, S J Gendler, L J Burgart, et al.
Kidney International. Supplement|February 1, 1986
Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTHH G Nebeker, D L Andress, D S Milliner, et al.
Annals of Internal Medicine|December 1, 1984
Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophyD S Milliner, H G Nebeker, S M Ott, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 25, 2006
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKDDaniel Coyne, Muralidhar Acharya, Ping Qiu, et al.
Kidney International|June 1, 1987
Bone histologic response to deferoxamine in aluminum-related bone diseaseD L Andress, H G Nebeker, S M Ott, et al.
Growth Regulation|March 1, 1995
IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domainB A Booth, M Boes, D L Andress, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 1, 1985
Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndromeK C Norris, P W Crooks, H G Nebeker, et al.
American Journal of Nephrology|June 13, 2009
The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristicsH J Lambers Heerspink, R Agarwal, D W Coyne, et al.
Pageof 10